Home›Companies›Healthcare›Magnus

Magnus Medical, Inc.

Makes a brain stimulation treatment for adults with depression who have not improved with medication.

Updated Nov 10, 2026·Latest SEC filing May 26, 2026·Suggest an edit

About Magnus

Magnus is a private company based in Burlingame, California. It has reported $89,332,372 raised in two offerings on Form D since March 2025. Its chief executive is Achal Achrol.

Funding Rounds (SEC Form D)

First saleFiled with SECAmount soldInvestorsAvg. checkTermsFiling
May 1, 2025May 12, 2025amended May 26, 2026$49,030,035of $77.0M target10$4.9MEquityRule 506(b)Form D/A ↗1 earlier filing
Feb 7, 2025Mar 14, 2025$40,302,337of $58.9M target10$4.0MEquityRule 506(b)Form D ↗
Total, two offerings$89,332,372

First sale is the date the first investor in the offering committed to invest. Companies must file Form D within 15 days of that date, so filing dates run later.

Leadership Team

Executive officers and directors listed on Magnus's Form D filed May 26, 2026.

HL
Heath Lukatch
Chairman of the Board
Also a director at CARGO Therapeutics.
AF
Andrew Firlik
Board Member
AA
Achal Achrol
Chief Executive Officer and director
BB
Brandon Bentzley
Co-Founder & Chief Medical Officer, director

Earlier filings also listed Xingjuan Chao (director, last listed Mar 2025), Vikram Lamba (executive officer, last listed Mar 2025), Nolan Williams (director, last listed Mar 2025) and Christian Gormsen (chief executive officer and director, last listed Mar 2025).

Sources

  1. SECMagnus Medical, Inc. Form D, filed May 12, 2025
  2. SECMagnus Medical, Inc. filing history
  3. CompanyPrivacy policy
  4. CompanyLearn About Magnus